Abstract: A device for transferring a toxic substance from a dispensing vessel to at least one receiving vessel comprising: (i) a receiving portion arranged to receive a dispensing vessel containing a toxic substance; and (ii) a transfer apparatus having a first infusion line adapted for fluid communication with the dispensing vessel to transfer a carrier fluid into said vessel and a second infusion line having one end adapted for fluid communication to withdraw and transfer the carrier fluid and the toxic substance from the dispensing vessel and the other end of the second infusion line arranged to connect with the at least one receiving vessel.

Abstract: The invention relates to a particulate material having a diameter in the range of from 5 to 200 microns comprising polymeric matrix stably incorporated radionuclide, processes for its production and method of radiation therapy utilising the particulate material.

Abstract: A method of treating cancer in a patient comprising administering to the patient an a systemic chemotherapeutic drug regime in combination with radioactively doped particle, characterised in that the two therapies when introduced into the patient have an improved anticancer effect.

Abstract: Accordingly, the present invention provides a method of treating lung neoplasia in a subject in need of treatment, by subjecting the patient to SIRT.

Abstract: A device for transferring a toxic substance from a dispensing vessel to at least one receiving vessel comprising: (i) a receiving portion arranged to receive a dispensing vessel containing a toxic substance; and (ii) a transfer apparatus having a first infusion line adapted for fluid communication with the dispensing vessel to transfer a carrier fluid into said vessel and a second infusion line having one end adapted for fluid communication to withdraw and transfer the carrier fluid and the toxic substance from the dispensing vessel and the other end of the second infusion line arranged to connect with the at least one receiving vessel.

Abstract: A method of treating cancer in a patient comprising administering to the patient an a systemic chemotherapeutic drug regime in combination with radioactively doped particle, characterised in that the two therapies when introduced into the patient have an improved anticancer effect.

Abstract: A microparticle composition(s) comprising nanomagnetic particles and a matrix, wherein said microparticle composition(s) have a least one of the following properties: (a) a VAR of at least about 1 Watts/cm3 subject to appropriate field conditions; (b) a density of about 2.7 or less: or (c) a size of about 100 nm to about 200 microns.

Abstract: The invention relates to a particulate material having a diameter in the range of from 5 to 200 microns comprising polymeric matrix and stably incorporated radionuclide, processes for its production and a method of radiation therapy utilising the particulate material.

Abstract: The invention relates to a particulate material having a diameter in the range of from 5 to 200 microns comprising polymeric matrix and stably incorporated radionuclide, processes for its production and a method of radiation therapy utilising the particulate material.

Abstract: The invention relates to a particulate material having a diameter in the range of from 5 to 200 microns comprising polymeric matrix and stably incorporated radionuclide, processes for its production and a method of radiation therapy utilising the particulate material.

Abstract: This invention relates to a particulate material comprising an inorganic low density, radiation tolerant core coated with a radionuclide, processes for its production and a method of radiation therapy utilizing the particulate material.

Abstract: The invention relates to a particulate material consisting of a low density radiation-tolerant glass and a radionuclide incorporated into the low density glass or coated on the low density glass, the glass having a density of less than 2.5 g/cm.sup.3, processes for its production and a method of radiation therapy utilising the patentable material.

Abstract: The invention relates to a particulate material consisting of a low density radiation-tolerant glass and a radionuclide incorporated into the low density glass or coated on the low density glass, the glass having a density of less than 2.5 g/cm3, processes for its production and a method of radiation therapy utilising the patentable material.

Abstract: The present invention concerns an unexpected synergistic combination of known antineoplastic therapies, which provides unexpectedly greater efficacy than either therapy alone in the treatment of neoplasia. Accordingly, the present invention provides a method that has utility in the treatment of various forms of cancer and tumours, but particularly in the treatment of brain and colorectal liver metastases and more specifically in the treatment of primary and secondary cancer of the liver. It is to be understood that the selective internal radiation therapies described herein should not be limited to radioactive microparticles, but may be extended to any radioactive particles that are suitable for use in the treatment methods described herein.

Abstract: A magnetic material having a magnetic heating efficiency of at least 4.5×10−8 J.m/A.g in a cyclic magnetic field where the product of the amplitude and frequency of the applied field is less than or equal to 5×108 A/m.s, and the frequency of the applied filed is at least 20 kHz. The ideal magnetic material is characterized by a perfectly rectangular hysteresis loop, i.e. loop squareness of 1, with coercivity of 25 kA/m or less and high saturation magnetization. Preferably the magnetic material has a predominately cubic magnetic crystalline anisotropy. Preferably the magnetic material is a substituted magnetite (Fe3O4) or &ggr;-ferric oxide (&ggr;Fe2O3) crystalline lattice in which some of the iron atoms in that crystalline lattice have been substituted for one or more alternate metals atoms. Desirably, the metal atom is a member of the group: cobalt, zinc, nickel, manganese, magnesium, copper, chromium, gallium, cadmium.

Abstract: A method for site specific treatment of diseased tissue in a patient, comprising the steps of: (i) selecting at least a magnetic material which has a magnetic heating efficiency of at least about 4.5×10−8 J.m./A.g, when magnetic field conditions are equal to or less than about 7.5×107 A/s; (ii) delivering the magnetic material to diseased tissue in a patient; and (iii) exposing the magnetic material in the patient to a linear alternating magnetic field with a frequency of greater than about 10 kHz and a field strength such that the product of field strength, frequency and the radius of the exposed region is less than about 7.5×107 A/s to generate hysteresis heat in the diseased tissue.

Abstract: A particulate material comprises hollow or cup-shaped ceramic microspheres having a diameter in the range of from 5 to 200 microns, the microspheres being formed from a base material comprising greater than 70% by weight of yttria or another yttrium-containing compound together with one or more compounds selected from the group consisting of alumina or another aluminium-containing compound, zirconia or another zirconium-containing compound, and silica or another silicon-containing compound. The particulate material may comprise a beta-radiation emitting radionuclide ytrrium-90, and be used in selective internal radiation therapy (SIRT) of various forms of cancer and tumors.

Abstract: A particulate material which comprises hollow or cup-shaped ceramic microspheres having a diameter in the range of from 5 to 200 microns. The material may comprise a beta- or gamma-emitting radionuclide and be used in selective internal radiation therapy (SIRT) of various forms of cancer and tumours.

Abstract: A method for site specific treatment of diseased tissue in a patient, comprising the steps of: (i) selecting at least a magnetic material which has a magnetic heating efficiency of at least about 4.5.times.10.sup.-8 J.m./A.g, when magnetic field conditions are equal to or less than about 7.5.times.10.sup.7 A/s; (ii) delivering the magnetic material to diseased tissue in a patient; and (iii) exposing the magnetic material in the patient to a linear alternating magnetic field with a frequency of greater than about 10 kHz and a field strength such that the product of field strength, frequency and the radius of the exposed region is less than about 7.5.times.10.sup.7 A/s to generate hysteresis heat in the diseased tissue.